Your browser doesn't support javascript.
loading
Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms: a nationwide cohort study.
Vujasinovic, Miroslav; Elbe, Peter; Ekheden, Isabella; Wang, Qiao-Li; Thuresson, Marcus; Roelstraete, Bjorn; Ghazi, Sam; Löhr, J-Matthias; Ludvigsson, Jonas F.
Affiliation
  • Vujasinovic M; Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Elbe P; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Ekheden I; Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Wang QL; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Thuresson M; Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Roelstraete B; Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Ghazi S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Löhr JM; Statisticon AB, Uppsala, Sweden.
  • Ludvigsson JF; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Scand J Gastroenterol ; 59(5): 600-607, 2024 May.
Article in En | MEDLINE | ID: mdl-38351653
ABSTRACT
BACKGROUND AND

AIMS:

Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precursor of pancreatic cancer. While earlier research has shown a high prevalence of synchronous/metachronous extrapancreatic tumors in IPMN patients, these studies have often been small with retrospective data collection. The aim of the study was to examine absolute and relative risks of non-pancreatic gastrointestinal (GI) cancer precursors and mortality in histologically confirmed IPMN.

METHODS:

Through the nationwide ESPRESSO histopathology cohort, we retrieved data on IPMN between 1965 and 2016. Each index case was matched to ≤5 general population controls. Through Cox regression, we estimated hazard ratios (HRs) for future GI cancer precursors and death.

RESULTS:

A total of 117 patients with IPMN and 539 age- and sex-matched controls were included. Over a median of 2.1 years of follow up, we confirmed two (1.7%) incident GI cancer precursors in IPMN vs. four (0.7%) in controls, corresponding to an HR of 1.89 (95%CI = 0.34-10.55). By contrast, IPMN patients were at increased risk of death (HR 3.61 (95%CI = 1.79-7.27)). The most common cause of death in IPMN was pancreatic cancer (n = 14; 45.2% of all deaths).

CONCLUSIONS:

We found no association between IPMN and other GI cancer precursors. This argues against comprehensive routine surveillance for other GI cancer precursors in IPMN patients. Mortality was increased in IPMN with pancreatic cancer being the most common cause of death, indicating the need for lifelong follow up in all resected and non-resected patients with IPMN. However, results should be confirmed in larger cohorts.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Pancreatic Intraductal Neoplasms / Gastrointestinal Neoplasms Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Scand J Gastroenterol Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Pancreatic Intraductal Neoplasms / Gastrointestinal Neoplasms Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Scand J Gastroenterol Year: 2024 Document type: Article Affiliation country: Country of publication: